Alto Neuroscience, Inc. ("Alto") , a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of ...
Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results